Seaport Therapeutics (SPTX) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Savara is the larger company by market cap ($1.01 billion vs $971.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SPTX | SVRA |
|---|---|---|
| Share price | $18.15 | $4.92 |
| Market cap | $971.58M | $1.01B |
| 1-day change | +1.34% | +1.86% |
| YTD return | — | -18.41% |
| 1-year return | — | +43.86% |
| 5-year return | — | +281.40% |
| EPS (TTM) | $-5.81 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-118.84M |
| 52-week high | $28.38 | $7.01 |
| 52-week low | $14.85 | $3.35 |
| Distance from 52-week high | -36.05% | -29.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +110.96% | +124.80% |
| Average volume | 182.45K | 1.83M |
| Shares outstanding | 53.53M | 205.46M |
| Employees | 58 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Seaport Therapeutics
SPTX stock →Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
SPTX vs SVRA FAQ
Which is bigger, Seaport Therapeutics or Savara?
Savara (SVRA) is larger, with a market capitalization of $1.01B compared with $971.58M for Seaport Therapeutics (SPTX).
Are Seaport Therapeutics and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.